一家守护着全球半数以上儿童生命健康的国际组织，日前成功"续命"。 "通过免疫接种实现健康与繁荣"全球峰会（以下简称"峰会"）日前在比利时首都布鲁塞尔举行，全球 疫苗免疫联盟（Gavi）在会上为未来五年（2026至2030年）筹措到了超90亿美元的资金，虽然离 119亿美元的预算目标仍有一定距离，但在全球健康融资断崖式下滑的当下，已难能可贵。 疫苗接种是最具成本效益的公共卫生干预手段之一。Gavi的核心宗旨是确保发展中国家的儿童能够 获得疫苗的保护，自2000年成立以来，已为全球超过10亿儿童接种了疫苗，成功预防了超过1800万 例可避免的死亡，如今为全球近一半的儿童提供基础疫苗服务，成为全球健康治理不可或缺的一环。 第一财经记者日前独家专访了全球疫苗免疫联盟（Gavi）首席执行官（CEO）尼什塔尔（Sania Nishtar），这是她在2024年1月就任以来，首次接受中文媒体的专访。她告诉第一财经记者，中国 是Gavi重要的合作伙伴，从最早接受Gavi支持到转变为如今的捐助国，Gavi希望在此基础上深化与 中国的合作。 ▲ 全球疫苗免疫联盟（Gavi）首席执行官（CEO）尼什塔尔 （来源：受访者提供） 202 ...

Core Points - The Global Vaccine Alliance (Gavi) successfully raised over $9 billion for the next five years (2026-2030) during the "Immunization for Health and Prosperity" summit in Brussels, despite a significant decline in global health financing [1][3] - Gavi has provided vaccines to over 1 billion children since its inception in 2000, preventing more than 18 million avoidable deaths, and currently serves nearly half of the world's children [1][3] - The UK and the Bill & Melinda Gates Foundation are the largest contributors, with the UK pledging £1.25 billion (approximately $1.6 billion) and the Gates Foundation contributing $1.6 billion [3] - The U.S. has historically been a significant donor, contributing around $300 million annually, but announced it would stop funding Gavi, which could impact global vaccination efforts [3][4] Funding and Contributions - The total commitments for the next five years include £1.25 billion from the UK, $1.6 billion from the Gates Foundation, and over €360 million from the European Commission and member states, totaling over €2 billion [3] - Indonesia, which recently graduated from Gavi's support list, pledged $30 million for the next five years, showcasing a shift from recipient to donor [5] Gavi's Operational Model - Gavi operates on a co-financing model where even low-income countries contribute a small amount per vaccine dose, gradually increasing their financial responsibility as their economies grow [5] - Gavi's CEO, Sania Nishtar, emphasized the importance of maintaining communication with the U.S. government to secure ongoing support [5] China's Role - China is highlighted as a successful example of Gavi's empowerment model, transitioning from a recipient to a donor, contributing over $120 million since 2016 [7] - The collaboration between China and Gavi began in 2002 with a hepatitis B vaccination program, significantly increasing vaccination rates in impoverished regions [7][8] Vaccine Development and Innovation - Gavi is focusing on expanding its vaccine portfolio, including support for vaccines against hepatitis E, tuberculosis, and monkeypox, as part of its 6.0 vaccine investment strategy [8][9] - Gavi is interested in innovative delivery methods, such as microneedle patches, to improve vaccine accessibility in low-resource settings [9][10] Leadership and Vision - Sania Nishtar, the first CEO from a developing country, brings a unique perspective to Gavi, having witnessed the impact of vaccine-preventable diseases firsthand [12][13] - Nishtar's background as a physician and public health advocate informs her commitment to ensuring health and immunization as fundamental human rights [13]

中办、国办印发《关于进一步保障和改善民生着力解决群众急难愁盼的意见》。意见提出，促进包容共 享发展。在公共政策制定、公共设施建设、公共服务供给中落实儿童优先原则和儿童友好理念。提升儿 童福利服务机构日常生活照料、基本医疗、基本康复、教育权益保障、社会工作能力。深化"爱心妈 妈"结对关爱，帮助解决留守儿童、困境儿童亲情陪伴、安全照护等方面的实际问题。完善孕期妇女产 前检查基本服务，鼓励有条件的地方为适龄女孩接种人乳头瘤病毒(HPV)疫苗。全面推进城乡公共空间 适儿化、适老化和无障碍改造。完善社会保险、社会福利、税收等方面支持家庭发展政策。(新华社) ...

昨天，发生了哪些财经大事？ "多半袋面"中的"多半"是商标？ 白象致歉 近日，多位网友反映称，白象多半袋面、多半桶面系列产品包装上显示"多半"为注册商 标，并质疑企业"在宣传上玩文字游戏"，消息引发热议。对此，白象食品官方客服人员表 示，"'多半'确实是商标，产品具体克重以包装上显示的为准，本身产品是没有问题的。" 4日晚间，白象食品发布声明称，目前公司在售的"多半"产品，是基于原70克面饼基础上推 出的110-120克面饼的大份量产品。"多一半"是基于原60克面饼推出的100克面饼的产 品。"多半"商标申请注册的初心是为了与常规份量产品做区分，便于消费者选购。如因此 给消费者造成误解，公司诚挚地表示歉意。后续公司将尽快调整"多半"产品包装，避免引 发消费者的误解。 首个国产九价HPV疫苗获批上市 4日，我国第一款九价人乳头瘤病毒（HPV）疫苗获国家药监局批准上市。这款疫苗是全球 第二款九价HPV疫苗，打破了国外产品长达十余年的市场垄断。 美联储"褐皮书"显示经济前景悲观 关税推升物价及生产成本 据央视新闻，当地时间4日，美联储发布的最新一期全国经济形势调查报告（简称"褐皮 书"）显示，美国经济活动自上次报告 ...

【重点关注】 ·中央财政拟支持北京、天津等20城实施城市更新行动 ·乘联分会：预估5月全国新能源乘用车厂商批发销量124万辆，同比增长38% ·韩国总统李在明正式宣誓就职 【国内要闻】 ·近日，市场监管总局印发《计量数字化转型攻坚行动方案》。《方案》提出，到2030年，重点突破30 项以上数字计量关键核心技术，研制10项具有自主知识产权的数字计量装置，培育80家左右国家计量数 据建设应用中心，建立国家计量数据中心，在重点领域重点行业建立5家智慧计量实验室，建成10个以 上国家标准参考数据库，挖掘和推广200个计量数据应用优秀案例。 ·今年前4个月，全国新开工改造城镇老旧小区5679个。分地区看，河北、重庆、辽宁、上海、浙江、湖 北等6个地区开工率超过50%。 ·乘联分会根据月度初步乘联数据综合预估，5月全国新能源乘用车厂商批发销量124万辆，同比增长 38%，环比增长9%。综合预估今年1-5月累计批发522万辆，同比增长41%。 ·南通市住房公积金管理中心发布关于优化住房公积金使用政策的通知，其中指出，个人住房公积金最 高贷款额度由60万元／人调整为70万元／人，每户住房公积金最高贷款额度由120万元／户调整 ...

Core Insights - The Chinese pharmaceutical industry is undergoing a significant transformation driven by demographic changes, evolving healthcare demands, and regulatory reforms [2] - The 2025 China Market Enterprise Transformation Index highlights three key success factors for leading pharmaceutical companies: drug research and development pipeline, R&D investment, and business resilience [2] - Despite challenges such as institutionalized drug procurement affecting profit margins, companies with strong balance sheets and diverse product portfolios are better positioned to adapt to regulatory changes [2] Industry Trends - The government's strategic initiatives, such as the "Action Plan for High-Quality Development of the Pharmaceutical Industry (2023-2025)," play a crucial role in supporting pharmaceutical innovation [2] - The increasing focus on preventive healthcare post-pandemic has created new opportunities, particularly in the vaccine and biopharmaceutical sectors [2] Company Performance - Novo Nordisk has significantly improved its ranking, moving from 13th in 2024 to 1st in 2025, driven by R&D investment and diversification into the obesity treatment market [6] - Jiangsu Hengrui Medicine ranked 3rd in 2025, reflecting its strong financial stability and competitive drug R&D pipeline, with a revenue of 22.82 billion RMB in 2023, a 7.26% increase year-on-year [7] - China National Pharmaceutical Group (CSPC) moved from 8th to 4th place, focusing on expanding its R&D pipeline and global research initiatives [8] - Chongqing Zhifei Biological Products Co., Ltd. saw the largest ranking increase, from 15th to 5th, capitalizing on the growing demand for HPV and respiratory vaccines [8] - Pfizer dropped from 1st to 7th place due to decreased post-pandemic product demand and intensified competition from domestic firms [9] Key Factors for Success - Strong R&D capabilities are essential for market leadership, as evidenced by the significant advancements of companies like Novo Nordisk and Hengrui [10] - Financial strength is critical for navigating policy changes, with companies like Hengrui demonstrating resilience through effective cash flow management [10] - A diverse R&D pipeline enhances market resilience, allowing companies to better withstand regulatory changes [10] - Vaccines are becoming a major growth driver, with increased investment in preventive healthcare reshaping the pharmaceutical landscape [10] - Accessibility to healthcare drives market opportunities, with companies balancing innovation and cost-effectiveness to meet the needs of the growing middle class and aging population [11]

人的一生都会面临传染病威胁，好在科学带来了疫苗这一有力武器，保护我们从出生到老年的健康。疫苗不只是 童年的"健康盾牌"，也是成年后的"健康卫士"。 01 儿童期： 筑牢免疫基石 宝宝的免疫系统尚未完全成熟，容易受到细菌、病毒等"敌人"的侵袭。疫苗接种能帮助身体提前识别"敌人"的特 征，建立高效的防御屏障。研究显示，儿童按照免疫程序及时全程地接种疫苗可有效预防相应传染病，疫苗是守 护孩子健康成长的关键盾牌。 给儿童家长的接种建议： 1.按照最新的《国家免疫规划疫苗儿童免疫程序表》和本省的疫苗接种方案为宝宝及时接种疫苗，筑牢预防传染 病的基础防线。 2.非免疫规划疫苗能填补免疫规划疫苗的防护空白，在预防传染病方面发挥重要作用。可结合孩子健康状况、医 生建议等接种肺炎球菌疫苗、轮状病毒疫苗、b型流感嗜血杆菌（Hib）疫苗、流感疫苗等，给孩子更多保护。 02 青少年和成人期： 容易被忽视的"免疫空白" 很多人以为，打疫苗只是儿童时期的事，长大后就不需要了。其实，由于疫苗接种不全或既往获得的免疫力随时 间减退，青少年和成人常成为被忽视的"免疫薄弱人群"，非常需要疫苗的保护。 给青少年家长和成年人的接种建议： 1.查漏补 ...